Evidence map›Paper›PMID 40057928›Full record

ArticleInflammopharmacology2025

Neuroprotective efficacy of berberine and caffeine against rotenone-induced neuroinflammatory and oxidative disturbances associated with Parkinson's disease via inhibiting α-synuclein aggregation and boosting dopamine release.

Tasnim S Waheeb, Mohammad A Abdulkader, Doaa A Ghareeb, Mohamed E Moustafa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction.International journal of environmental research and public health · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tasnim S WaheebDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt. tasnim.waheeb@alexu.edu.eg.ORCID http://orcid.org/0009-0005-5988-6883
Mohammad A AbdulkaderDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt.
Doaa A GhareebBio-Screening and Preclinical Trial Lab, Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Mohamed E MoustafaDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by motor impairment, glial-mediated inflammation, redox imbalance, and α-synuclein (α-syn) aggregation. Conventional therapies relieve early PD symptoms, but they do not repair dopaminergic neurons. Berberine (BBR) and caffeine (CAF), both natural alkaloids, exhibited neuroprotective effects in many neurodegenerative disorders. Consequently, we hypothesized that the combination of BBR and CAF therapies would offer protection against PD-related impairments in the rotenone (ROT)-induced rat model when compared to the commercial drug, metformin (MTF). Our results showed that the combined administration of BBR (25 mg/kg/day) and CAF (2.5 mg/kg/day) for four weeks prevented motor deficits, weight reduction, dopamine (DA) depletion, and monoamine oxidase (MAO) activity in ROT-induced rats in comparison with monotherapy of BBR and CAF along with MTF. This combination produced a notable neuroprotective effect by reducing tumor necrosis factor (TNF)-α and interleukin-16 (IL-6) in midbrain of rats. BBR and CAF combinations markedly normalized tyrosine hydroxylase (TH) levels and decreased total α-syn and α-syn-p

Indexed as

alpha-SynucleinBerberineCaffeineDopamineNeuroinflammatory DiseasesNeuroprotective AgentsParkinson DiseaseAnimalsDisease Models, AnimalDopaminergic NeuronsMaleMetforminOxidative StressRatsRats, Sprague-DawleyRotenonealpha-SynucleinBerberineCaffeineDopamineMetforminNeuroprotective AgentsRotenoneMolecular dockingMotor impairmentNatural combination therapyNeurodegenerative diseasesProtein phosphatase 2ARotenone modelTyrosine hydroxylase

Identifiers

PMID40057928
PMCPMC11991993

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.